Disease recurrence in patients with Crohn’s disease after biologic therapy or surgery: a meta-analysis

Sarah Kneißl1 · Johannes Stallhofer1 · Peter Schlattmann2 · Andreas Stallmach1

Accepted: 18 September 2022 / Published online: 23 September 2022
© The Author(s) 2022, corrected publication 2022

Abstract
Background Relapse is a problem in patients with Crohn’s disease (CD) after medical therapy (including biologics) and after surgery to treat acute inflammation. It is unclear whether the recurrence rate over time is higher after surgical therapy than after continuous drug treatment.

Aim We sought to compare clinical relapse rates and the need for re-interventions (resection or therapeutic endoscopic intervention) in patients with CD.

Methods A meta-analysis was performed according to PRISMA guidelines.

Results The need for re-intervention with medication or surgery due to surgical or clinical recurrence increased over time. The recurrence rates in patients after ileocecal resection were lower than the rates under biologic therapy. The odds ratio for clinical recurrence under biologics versus after surgical treatment was 2.50 (95% confidence interval [CI] 1.53–4.08, p-value < 0.001). The odds ratio for surgical recurrence under biologics versus after surgery was 3.60 (95% CI 1.06–12.3, p-value 0.041).

Conclusion These findings support surgical resection as a treatment option in patients with CD with limited disease.

Keywords Crohn’s disease · Infliximab · Adalimumab · Resection · Recurrence

Introduction
Crohn’s disease (CD) is a chronic inflammatory bowel disease of unclear aetiology that usually affects young adults and children, with a peak incidence between the ages of 15 and 35. In western industrialised countries, the incidence is 6–15 per 100,000, and the prevalence is 50–200 per 100,000. In recent decades, the incidence and prevalence have increased globally [1]. Maintaining remission of CD is a central goal in clinical practice. Recurrence of CD has a strong negative impact on health and quality of life [2]. Therapeutic concepts for maintaining remission are usually based on medical therapy alone. The standard step-up concept using immunosuppressants and biologics is guided by German and international guidelines [3].

Immunomodulatory treatment aims to prevent clinical relapses and repeat surgery.

Against this background, the number of patients treated long-term with biologics such as anti-TNF antibodies has risen over the last few years. In contrast, surgery remains a treatment option. Its benefits were recently confirmed in the LIR!C trial. In that study, the biologics and surgery groups showed comparable results in terms of quality of life with no additional severe side effects [2]. However, the long-term course for patients with initial infliximab therapy was characterised by more frequent ileocecal resection. In contrast, the initially resected patients had to start infliximab therapy significantly less often due to a recurrence. These findings suggest that ileocecal resection is a viable alternative to biologics in patients with an isolated ileitis terminalis [4].

Recently, studies on the various treatment options and their effects focused on only one treatment option. Nevertheless, some patients may benefit from earlier surgery followed by biologic therapy to maintain remission. Therefore, in our meta-analysis, we included ileocecal resection, administration of biologics or a combination of both. We compared the results regarding clinical recurrence and the need for surgical re-intervention or endoscopic balloon dilatation.
The present study aimed to compare medical and surgical treatment strategies and to derive possible therapy suggestions that are likely to optimise outcomes.

**Methods**

The following “Methods” section was structured according to the PRISMA guidelines.

**Eligibility criteria**

Clinical trials, meta-analyses, randomised controlled trials, reviews and systematic reviews with pro- and retrospective, placebo-controlled, randomised and double-blinded designs were included. To generate the most significant number of patients, the following patients were included: non-naive patients (regarding previous medication), concomitant and post-interventional medication and previous operations. Our exclusion criteria were as follows: (1) ‘books and documents’, (2) children up to the age of twelve, (3) follow-up within 30 days and (4) mixed populations of ulcerative colitis and CD patients.

**Information sources and search strategy**

We obtained full-text articles from PubMed. The date the database was last consulted was the 3rd of June 2022. To locate articles relating to outcomes after ileocecal resection for CD, our search terms included ‘Crohn's disease’, ‘ileocecal resection’, ‘recurrence’ and ‘outcome’.

For the treatment with biologics and the combination of resection and biologics, our terms included ‘recurrence of Crohn* after infliximab/adalimumab’.

Regarding the combination therapy defined by the use of biologics after resection, the search criteria included ‘ileocecal resection and biologics Crohn*’ and ‘Crohn infliximab/adalimumab post-operative’.

**Selection and data collection process**

In this meta-analysis with logistic regression, we included studies focusing on patients with CD who underwent surgery with or without drug therapy with biologics. Patient data from these studies were extracted and compared depending on the intervention.

All eligible studies were reviewed and selected according to the following primary endpoints: Clinical recurrence and surgical recurrence (= need for re-intervention/dilatation). Clinical relapse was defined based on Crohn’s Disease Activity Index (CDAI) scores [5]. The introduction or intensification of CD-related medications is also defined as clinical recurrence.

Surgical recurrence was defined as the need for re-operation in the ileocecal resection arm and the need for surgery in the biologics arm. The studies were assigned to one of the three treatment groups (ileocecal resection, use of biologics (infliximab or adalimumab), resection with following use of biologics) in an Excel table.

**Data items**

From each trial, data were extracted regarding study design, publication year, type of therapy, application info, follow-up times, number of participants, gender, recurrence-free years, target criteria (clinical, endoscopic, or surgical recurrence) and their time of onset, pre- and post-medication and pre-operations.

**Synthesis methods**

A consort diagram was prepared for a more straightforward presentation of study identification throughout the inclusion or exclusion of studies. Because not all variables from the original Excel file were needed for our meta-analysis, a table was created for each treatment option (ileocecal resection, biologics and combination therapy). The tables contained the variables study number, author, year, participants, male, female, follow-up time and definition of relapse.

**Statistical analysis**

Because there are almost no trials that describe a direct head-to-head comparison of medical and surgical treatment regimens, we performed a meta-analysis of proportions (incidence). The incidence represented the ratio of patients with complications to the total number of patients in that study at a specific time. This analysis was performed at various times (e.g. 12 and 60 months). To perform a combined analysis, we applied a random intercept logistic regression model with covariate treatment (surgery, biologics and combination therapy) and time because several studies reported more than one time that induced correlated data. We used the model-based odds ratio with a 95% confidence interval (CI) to examine treatment comparisons and time effects.

Analysis of heterogeneity of incidences across studies was initially performed using Cochran’s $Q$-test. The degree of heterogeneity was also quantified using $I^2$ values. The $I^2$ statistic describes the percentage of variation across studies due to heterogeneity rather than chance. This meta-analysis estimated the heterogeneity variance $\tau^2$ based on the maximum likelihood estimate according to the random effects logistic regression model.
Publication bias was investigated using Egger’s regression test and represented by funnel plots for surgical and clinical recurrence [6] (Suppl Figs. 1 and 2).

All statistical analyses were performed using R (version 1.4.1717) and the corresponding packages lme4 [7] and metaprop [8].

**Results**

Two authors (SK, AS) performed a literature search in PubMed to locate studies evaluating the efficacy of biologics, surgical resections and combination therapies (resection and post-operative introduction of biological therapy). Our search strategy identified 2257 references (Fig. 1).

Of these, 112 were eligible, published between 1983 and 2021. Sixty-five were excluded because of inappropriate study designs (follow-up only for 30 days) or other endpoint definitions for achieving recurrence. One article was excluded because of inappropriate data sets. After reviewing all studies and collecting the results, we determined that the endpoint of endoscopic recurrence was not suitable for comparing different relapse-preventing therapies because the possible treatment goals of the interventions differed across studies. While surgery resects the affected bowel segment and optimally removes all endoscopic lesions, the administration of biologics can lead to mucosal healing. Still, it may (in many patients) only prevent the endoscopic lesions from progressing and spreading. Therefore, the data collected on endoscopic recurrence were not included. This exclusion affected five studies in the ileocecal resection arm, two in the biologics arm, and six in the combination arm. Overall, 33 studies with 4220 participants were considered in our meta-analysis. For surgical recurrence, we found publication bias according to Egger’s regression test with a bias equal to —2.6518 and $p$-value = 0.0143 (Supplementary Fig. 1). For clinical recurrence, there was no publication bias (bias — 0.4064 and $p$-value = 0.6878) (Supplementary Fig. 2).

Most studies in our meta-analysis were published in the early 2000s. Of the 33 studies, ten described patients with ileocecal resections as one of the three treatment groups; 12 focused on medical treatment with infliximab or adalimumab; and the remaining 11 included patients with sequential combination therapies with surgical resections and subsequent use of infliximab or adalimumab. Baseline information and patient characteristics are shown in Tables 1–3.

**Clinical recurrence**

Clinical recurrence after ileocecal resection was defined as symptoms and the need for new medications like systemic steroids, immunosuppressives and biologics [9–11] or symptoms and radiological/endoscopic proof of recurrence [10, 12]. In the biological group, clinical recurrence was defined as the need for steroids or other medical intervention (dose intensification, switch to other biologics or introduction of combination therapies) [2, 13–20]. Other studies defined clinical recurrence based on a CDAI score $\geq$ 150 [18–22]. In the combination group (surgery + biologics), the CDAI score was used to define clinical recurrence. In most studies in the combination group, CDAI $> 150$ defined recurrence of disease [23–26], whereas three other studies [27–29] set their limit on a higher CDAI score or the need for an additional criterion (Table 3). In two studies, the patients had to show symptoms and a need for intervention (medication, re-operation) or radiologically confirmed disease activity [30, 31]. In one study, the authors used their clinical recurrence scale and defined recurrence as a Rutgeerts score $\geq 12$ [32].
Surgical recurrence

In the ileocecal resection group, surgical recurrence was defined by the need for re-operation [9, 10, 12, 33–36] or (in some studies) endoscopic dilatation [11, 37, 38]. In the biological group [2, 15, 17], the need for re-intervention/dilatation was already considered a surgical recurrence. In two studies [14, 39], only the need for major abdominal surgery was rated as a recurrence.

Overall evaluation

To create the opportunity to compare the three therapy options, ileocecal resection, use of biologics or combination

---

**Table 1** Characteristics of the included ileocecal resection studies

| Reference | Author | Year | Participants | Male | Female | Follow-up | Definition of relapse |
|-----------|--------|------|--------------|------|--------|-----------|----------------------|
| [37]      | Aaltonen et al. | 2018 | 92 | 55 | 37 | 60 mo | Need for endoscopic dilatation or surgical reintervention |
| [33]      | Kim et al. | 1997 | 181 | 79 | 102 | 60 mo | Re-OP |
| [38]      | Rink et al. | 2014 | 119 | 37 | 82 | 60/120 mo | Symptomatic restenosis with need for dilatation or Re-OP |
| [9]       | De Buck van Overstraeten et al. | 2017 | 538 | 215 | 323 | 12/60/120 mo | Need for medication or intensification of treatment; Re-OP |
| [34]      | Yamamoto et al. | 1999 | 141 | 17 | 45 | 96 mo | Re-OP |
| [10]      | Margagnoni et al. | 2011 | 212 | 120 | 92 | 120 mo | Symptoms with need for steroids or budesonid in the presence of endoscopic +/- radiological recurrence; Re-OP |
| [12]      | Cullen et al. | 2007 | 139 | 55 | 84 | 60/84/120 mo | Symptoms + radiological/endoscopical proof; Re-OP |
| [35]      | Rutgeerts et al. | 1990 | 119 | 37 | 82 | 60/120 mo | Rutgeerts’ ≥ i1; Re-OP |
| [11]      | Rivière et al. | 2021 | 365 | 155 | 210 | 6.2/88 mo | Rutgeerts’ ≥ i1; Dilatation or Re-OP; need for IMM or biologicals |
| [36]      | Riss et al. | 2014 | 116 | 66 | 50 | 60/120 mo | Re-OP |

Table 1 shows the characteristics of the studies included in the meta-analysis for the ileocecal resection treatment. Noticed that most of the studies defined relapse as the need for re-operation (Re-OP). The studies in the table are broken down by author, publication year, number of participants, gender, follow-up in months, and definition of relapse.

---

**Table 2** Characteristics of the included biologics studies

| Reference | Author | Year | Participants | Male | Female | Follow-up | Drug | Definition of relapse |
|-----------|--------|------|--------------|------|--------|-----------|------|----------------------|
| [13]      | Colombel et al. | 2010 | 169 | 84 | 85 | 6 mo | Infliximab | Need for corticosteroids; continuation of ulcerations |
| [14]      | Schnitzler et al. | 2009 | 614 | 240 | 374 | 55.3 mo | Infliximab | Major abdominal surgery (MAS); need for intervention (clinical) |
| [2]       | Stevens et al. | 2020 | 65 | 19 | 46 | 17/63.5 mo | Infliximab | Surgery; need for further IFX or switch of Medication |
| [39]      | Feagan et al. | 2008 | 517 | 197 | 320 | 12.8 mo | Adalimumab | Major abdominal surgery (MAS) |
| [15]      | Ho et al. | 2008 | 22 | 8 | 14 | 12 mo | Adalimumab | Surgery; ADA dose escalation |
| [16]      | Macaluso et al. | 2019 | 214 | 118 | 96 | 2.7/12 mo | Infliximab, Adalimumab | Need for steroids + symptoms |
| [17]      | Kestens et al. | 2013 | 100 | 45 | 55 | 12/24 mo | Infliximab, Adalimumab | Surgery; need for steroids |
| [21]      | Hinojosa et al. | 2007 | 36 | 11 | 25 | 1 mo | Adalimumab | CDAI ≥ 150 |
| [22]      | Seiderer et al. | 2007 | 16 | 8 | 8 | 1.8/5.5 mo | Adalimumab | CDAI ≥ 150 |
| [18]      | Colombel et al. | 2015 | 62 | 6 | 25 | 6 mo | Infliximab | CDAI ≥ 150; need for steroids; continuation of ulcerations |
| [19]      | Peyrin-Biroulet et al. | 2007 | 24 | 5 | 19 | 1/12 mo | Adalimumab | CDAI ≥ 150; need for steroids |
| [20]      | Cordero-Ruiz et al. | 2011 | 25 | 10 | 15 | 5.5/11 mo | Adalimumab | CDAI ≥ 150; need for steroids |

Table 2 shows the characteristics of the studies included in the meta-analysis for the treatment with biologics. Noticed that most of the studies defined relapse as the need for steroids and by using the CDAI-score. The studies in the table are broken down by author, publication year, number of participants, gender, follow-up in months, which drug was given (IFX and/or ADA), and definition of relapse.
of surgery and biologics regarding the different follow-ups, a random effects logistic regression model was applied for clinical and surgical recurrences. The following graphs (Figs. 2, 3, 5 and 6) show the probabilities of a clinical or surgical recurrence for the various therapy options after 12 or 60 months using a scale. The number 0 means no recurrence occurred in any study participant, and (for example) the value 0.5 means that half the participants suffered a recurrence within the defined period. A bubble plot for clinical and surgical recurrences was generated to clarify the results and compare the various therapy options regarding their recurrence rates (see below). These plots represent the logistically calculated recurrence rates of the three treatment options (surgery, biologics and both) over time. The circles in the plot represent the individual studies. Larger circles represent larger study populations. The y-axis shows the event rate (i.e. clinical recurrence (Fig. 4) and surgical recurrence (Fig. 7). The follow-up time in months is plotted on the x-axis.

After 12 months, the lowest risk of clinical recurrence was observed in the combination group, 0.13 (95% CI 0.07–0.22), followed by the surgical group at 0.18 (95% CI 0.15–0.21) and the biologic group at 0.36 (95% CI 0.25–0.50). The results had to be checked for significance to interpret the plot below. In the plot on clinical recurrence, the combination therapy ‘both’ also appeared as the best therapy option with the lowest probability of recurrence. However, this assumption was not statistically significant, as the p-value (Pr) for the combination therapy was 0.71. This finding suggests that ileocecal resection is associated with the best outcome in terms of clinical recurrence after 12 months (Fig. 2).

After 60 months, the clinical recurrence rates were similar between the surgery and biologics groups, with 0.45 (95% CI 0.36–0.55) for surgery and 0.48 (95% CI 0.39–0.58) for biologics. The surgical recurrence rates were 0.33 (95% CI 0.24–0.43) for surgery and 0.26 (95% CI 0.18–0.35) for biologics. The results had to be checked for significance to interpret the plot below. In the plot on surgical recurrence, the combination therapy ‘both’ also appeared as the best therapy option with the lowest probability of recurrence. However, this assumption was not statistically significant, as the p-value (Pr) for the combination therapy was 0.71.

Table 3 shows the characteristics of the studies included in the meta-analysis for the combination treatment with resection and biologics. Noticed that most of the studies defined relapse by using Rutgeerts’ score and CDAI-score. The studies in the table are broken down by author, publication year, number of participants, gender, follow-up in months, type of intervention, and definition of relapse.
0.41–0.50) in the surgery group and 0.44 (95% CI, 0.40–0.48) in the biologics group. No studies were found for 60 months from the therapy regime ‘both’. However, the results of the biologics group were not statistically significant, as their \( p \)-value (Pr) was 0.34 (Fig. 3).

In the first 25 months, clinical relapses occurred primarily with biologics therapy (event rate 0.2–0.6). Over time, recurrence rates increase with surgical treatment (event rate 0.35–0.55) (Fig. 4). These findings suggest that patients in the three therapy groups suffer a higher risk of recurrence over time.

After 12 months, the lowest risk of surgical recurrence was observed in the combination group (0.00 [95% CI, 0.00–1.00]), followed by the surgical group (0.01 [95% CI, 0.00–0.04]) and the biologic group (0.07 [95% CI, 0.01–0.37]). The combination group ‘both’ results were insignificant and therefore not meaningful, as their \( p \)-value (Pr) was 1.00 (Fig. 5).

After 60 months, the surgical recurrence rates were 0.11 (95% CI, 0.06–0.19) in the surgery group and 0.26 (95% CI, 0.23–0.30) in the biologics group. There were no studies from the combination therapy group for the probability of recurrence after 60 months. The results of the two types of therapy, surgery and biologics, were statistically significant (Fig. 6); more than twice as many surgical recurrences occurred in the biologics group after 60 months as in the surgical group.

In the first 25 months, surgical relapses occurred primarily with biologics therapy (event rate between 0.1 and 0.5). From 60 months and beyond, the recurrence rates increased with surgical treatment. Just as in the bubble plot for clinical recurrence, this plot showed an increase in surgical recurrence rates in all therapy groups over time (Fig. 7).

Table 4 displays the OR for clinical and surgical recurrence with combination therapy or biologics concerning recurrence...
rates with ileocecal resection. The OR for the biologics group was 2.50 (95% CI 1.53–4.08, p-value < 0.001), suggesting a higher risk of clinical recurrence with biologics than with ileocecal resection.

The table also shows that the risk of clinical recurrence increased by 1.19 with every year of therapy, regardless of therapy type. The OR for the biologics group was 3.60 (95% CI 1.06–12.3, p-value 0.041), suggesting that the surgical recurrence risk was higher than under surgical therapy. Here, the surgical recurrence risk also increased by 1.31 per year regardless of therapy type. The clinical and surgical recurrence rates under combination therapy ‘both’ were not statistically significant.

**Discussion**

Because CD is a chronic inflammatory condition that progresses and cannot be cured, it is critical to achieving sustained clinical remission. Current valid guidelines recommend
checking the indications for surgery before starting immuno-suppressive therapy (e.g. with biologics). Evidence for this recommendation was provided by the LIR!C trial using a head-to-head comparison between biologic administration and surgery with limited and predominantly inflammatory terminal ileitis for whom conventional treatment was unsuccessful [2]. This ground-breaking study was neither confirmed nor refuted. Against this background, we performed a detailed meta-analysis comparing surgical and drug treatment regarding the likelihood of recurrence.

In summary, surgical resection showed the best results over time in surgical and clinical recurrence, with the lowest recurrence rates compared to treatment with biologics (Table 4). Most included studies only considered one intervention and its outcome and not the individual treatment options in terms of different endpoints. Therefore, our meta-analysis acquired sufficient data from ileocecal resection, biologics (infliximab, adalimumab) and a combination of surgery and biologics. Based on a logistic regression model, 33 studies were compared regarding clinical recurrence and repeat surgical interventions. The finding might explain the robustness of the outcomes that the probability of recurrence increased for all three treatment options over time (Figs. 4 and 7, Table 4). The endpoint of endoscopic recurrence (initially considered) was not included in interpreting the results. However, endoscopic findings are becoming
increasingly crucial in therapy management and will be indispensable for optimising and individualising therapy in the future. Orlando et al. showed that it is helpful to perform early endoscopic follow-up to detect recurrences in time and counteract them [40].

A limitation of our study was that the studies set their follow-ups at different, non-uniform time points. Therefore, we used a logistic regression model to compare them. Nevertheless, it would have been desirable for the long-term course if several follow-ups had been made and reported in each study. Furthermore, we did not set a time frame for the publication year of the studies and included older studies from the 1990s (Tables 1–3). It must be kept in mind that some newer surgical procedures and biologics have only been developed recently. Moreover, the studies often did not have identical definitions of when relapse was reached (e.g. in the case of need for re-intervention/dilatation). Some studies defined minor interventions such as endoscopic dilatations as recurrence. Other studies defined only major surgeries as recurrence (Tables 1–3). It must also be kept in mind that different study-specific threshold values were set when using the CDAI for clinical recurrence and that this score also depends on the subjective perception of the patient (Tables 2 and 3). Furthermore, it was not able to differentiate between inflammatory or stenotic condition as an indication for re-intervention in the prior surgery group.

Our endpoint of endoscopic recurrence (defined initially) was not included in our interpretation because the two interventions, ileocecal resection and use of biologics, had different therapeutic starting points concerning endoscopy. Ileocecal resection aims to remove affected bowel segments with inflammatory and endoscopic abnormalities. This is considered an endoscopic recurrence if endoscopic abnormalities reappear post-operatively in the sections that were not resected. On the other hand, biologics attempt to treat existing endoscopic ulcerations/abnormalities. In this case, endoscopic recurrence cannot be used as the endpoint, as the affected foci were never thoroughly removed and subsequently recurred. The only statement that can be made concerns how biologics affect mucosal healing. Statements were only made about the biologics infliximab and adalimumab, as there were too few data for others (e.g. ustekinumab and vedolizumab). Finally, we could not achieve a homogeneous patient population with the same baseline characteristics because the individual studies each set different inclusion and exclusion criteria. Therefore, the patients differed in prior medication and surgery, concomitant medication, sex, smoking status and age.

Our meta-analysis is further limited by publication bias in the surgical recurrence arm. This bias could not be mitigated. An additional literature search of PubMed and the internet yielded no further matching manuscripts. In summary, our meta-analysis suggests that surgical resection is associated with better outcomes in terms of clinical recurrence and the need for re-intervention/dilatation than monotherapy with biologics or combination therapy. The results are robust and well suited for counselling patients before starting immunomodulatory treatment. They also support the recommendations in the current guidelines for treating CD [2].

Supplementary information The online version contains supplementary material available at https://doi.org/10.1007/s00384-022-04254-z.

Author contribution Sarah Kneißl, Johannes Stallhofer and Andreas Stallmach analysed the data and wrote the manuscript text. Sarah Kneißl and Peter Schlattmann prepared the statistics and figures. All the authors reviewed the manuscript. Guarantor of the article: Andreas Stallmach.

Funding Open Access funding enabled and organized by Projekt DEAL. The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This work was supported by the Interdisciplinary Center of Clinical Research (IZKF) of the Medical Faculty Jena (Advanced Clinician Scientist Program ACSP 05 to JS).

Declarations

Competing interests JS received travel support from MSD Sharp & Dohme, AbbVie and Pfizer. PG obtained consulting fees from Janssen and Takeda and lecture fees and travel support from AbbVie, Janssen, Pfizer and Takeda. A Stallmach reports research funding from AbbVie and Celltrion and has received lecture fees from AbbVie, Amgen, Astellas, Biogen, Celltrion, Institut Allergosan, Janssen, Falk Foundation, Ferring, MSD, RecordatiPharma, Streamed-Up and Takeda and consulting fees from AbbVie, Astellas, Amgen, Biogen, CSL Behring, Consal, Galapagos, Hexal, Janssen, MSD, Norgine, Pfizer Pharma, Takeda and Tillots Pharma.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A (2011) Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 140(6):1785–1794
2. Stevens TW, Haasnoot ML, D’Haens GR, Buskens CJ, De Groof EJ, Eshuis EJ, Gardenbroek TJ, Mol B, Stokkers PCF, Bemelman WA, Ponsioen CY, LIR!C study group (2020) Laparoscopic
ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: retrospective long-term follow-up of the LIR/C trial. Lancet Gastroenterol Hepatol 5(10):900–907
3. Sturm A, Atrey A, Bettenworth D, Bokemeyer B, Dignaß A, Ehehalt R, Germer C, Grunert PC, Helwig U, Herrlinger K, Kienle P, Kreis ME, Kucharzik T, Langhorst J, Maaser C, Ockenga J, Ott C, Siegmund B, Seilig S, Stallmach A (2021) Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). AWMF online (021–004) 60(3):332–418
4. Reibetanz J, Germer CT (2018) Laparoscopic ileocaecal resection compared with infliximab for terminal ileitis. Chirurg 89(2):157
5. Best WR, Becktel JM, Singleton JW, Kern F Jr (1976) Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study Gastroenterology 70(3):439–444
6. Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634
7. Bates D, Maechler M, Bolker B, Walker S (2015) Fitting linear mixed-effects models using lme4. J Stat Softw 67(1):1–48
8. Balduzzi S, Rücker G, Schwarzer G (2019) How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 22(4):153–160
9. Buck De, van Overstraeten A, Eshuis EJ, Vermeire S, Van Assche G, Ferrante M, D’Haens GR, Ponsioen CY, Belmans A, Buskens CJ, Wohlhaus AM, Bellemann WA, D’Hoore A (2017) Short- and medium-term outcomes following primary ileocaecal resection for Crohn’s disease in two specialist centres. British Journal of Surgery Society Limited 104(12):1713–1722
10. Margagnoni G, Aratari A, Mangone M, Moretti A, Spagnolo A, Fasci Spurio F, Luchetti R, Papi C (2011) Natural history of ileo-caecal Crohn’s disease after surgical resection. A long term study. Minerva Gastroenterol Dietol 57(4):335–344
11. Rivière P, Vermeire S, Irles-Depe M, Van Assche G, Rutgeerts P, Denost Q, Wohlhaus A, D’Hoore A, Laharie D, Ferrante M (2021) Rates of postoperative recurrence of Crohn’s disease and effects of immunosuppressive and biologic therapies. Clin Gastroenterol Hepatol 19(4):713–720
12. Cullen G, O’Toole A, Bokemeyer B, Dignaß A, Bettenworth D, Ehehalt R, Germer C, Grunert PC, Helwig U, Herrlinger K, Kienle P, Kreis ME, Kucharzik T, Langhorst J, Maaser C, Ockenga J, Ott C, Siegmund B, Seilig S, Stallmach A (2021) Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). AWMF online (021–004) 60(3):332–418
13. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rutgeerts P, Tang KL, Oortwijn A, Bevelander GS, Cornillie FJ, Sandborn WJ (2015) Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn’s disease – a SONIC post hoc analysis. Aliment Pharmacol Ther 41(8):734–746
14. Peyrin-Biroulet L, Lacroix C, Bigard MA (2007) Adalimumab maintenance therapy for Crohn’s disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther 25(6):675–680
15. Cordero-Ruiz P, Castro-Márquez C, Méndez-Rufián V, Castro-Lario L, Caunedo-Álvarez A, Romero-Vázquez J, Herreras-Gutiérrez JM (2011) Efficacy of adalimumab in patients with Crohn’s disease and failure to infliximab therapy: a clinical series. Revista Española de Enfermedades Digestivas 103(6):294–298
16. Hinojosa J, Gomollón F, García S, Bastida G, Gabriela JL, Sgarbado D, Peñate M, Gassull MA (2007) Efficacy and safety of short-term adalimumab treatment in patients with active Crohn’s disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther 25(4):409–418
17. Seiderer J, Brand S, Dambacher J, Pfennig S, Jürgens M, Göke B, Ochsenuhn K (2007) Adalimumab in patients with Crohn’s disease – safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther 25(7):787–796
18. Yoshida K, Fukunaga K, Icheku H, Kamekojiro K, Hida N, Ohda Y, Yokoyama Y, Imuro M, Takeda N, Kato K, Kikuyama N, Nagase K, Hori K, Nakamura S, Miwa H, Matsumoto T (2012) Scheduled infliximab monotherapy to prevent recurrence of Crohn’s disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. Inflamm Bowel Dis 18(9):1617–1623
19. Fukushima K, Sugita A, Futami K, Takahashi K, Motoya S, Kimura H, Yoshikawa S, Kinouchi Y, Ijiima H, Endo K, Hibi T, Watanabe M, Sasaki I, Suzuki Y, Surgical Research Group, the Research Committee of Inflammatory Bowel Disease, the Ministry of Health, Welfare and Labor of Japan (2018) Postoperative therapy with infliximab for Crohn’s disease: a 2-year prospective randomized multicenter study in Japan. Surg Today 48(6):584–590
20. Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, Harrison J, Plevy SE (2009) Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology 136(2):441–450
21. Asada T, Nakayama G, Tanaka C, Kobayashi D, Ezaka K, Hattori N, Kanda M, Yamada S, Koike M, Kodera Y (2018) Postoperative adalimumab maintenance therapy for Japanese patients with Crohn’s disease: a single-center, single-arm phase II trial (CCOG-1107 study). Surg Today 48(4):609–617
22. Marteau P, Le`mann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, Cadiot G, Soulé JC, Bourreille A, Metman E, Lerebours E, Carbonnel F, Dupas JL, Veyrac M, Abitbol V, Moreau J, Caunedo-Álvarez Á, Romero-Vázquez J, Herreras-Gutiérrez JM (2011) Efficacy of adalimumab in patients with Crohn’s disease and failure to infliximab therapy: a clinical series. Revista Española de Enfermedades Digestivas 103(6):294–298
23. Peyrin-Biroulet L, Laclotte C, Bigard MA (2007) Adalimumab and infliximab are equally effective for Crohn’s Disease in Patients Not Previously Treated With Anti-Tumor Necrosis Factor - Agents. Clin Gastroenterol Hepatol 11(7):826–831
24. Veldhuizen AA, Van Bodegraven AA, Kornbluth A, Rutgeerts P, Tang KL, Oortwijn A, Bevelander GS, Cornillie FJ, Sandborn (2015) Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn’s disease – a SONIC post hoc analysis. Aliment Pharmacol Ther 41(8):734–746
25. Peyrin-Biroulet L, Lacroix C, Bigard MA (2007) Adalimumab maintenance therapy for Crohn’s disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther 25(6):675–680
26. Mohammad B, Arnott I, Cahill A, Smith M, Ahmad T, Subramanian S, Travis S, Morris J, Hamlin J, Dhar A, Nwokolo C, Edwards C, Creed T, Bloom S, Yousif M, Thomas L, Campbell S, Lewis SJ, Sebastian S, Sen S, Lal S, Hawkey C, Murray C, Cummings F,
Goh J, Lindsay JO, Arebi N, Potts L, McKinley AJ, Thomson JM, Todd JA, Collie M, Dunlop MG, Mowat A, Gaya DR, Winter J, Naismith GD, Ennis H, Keerie C, Lewis S, Prescott RJ, Kennedy NA, Satsangi J (2016) Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. Lancet Gastroenterol Hepatol 1(4):273–282

30. Aguas M, Bastida G, Cerrillo E, Beltrán B, Iborra M, Sánchez-Montes C, Muñoz F, Barrio J, Riestra S, Nos P (2012) Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients. World J Gastroenterol 18(32):4391–4398

31. Cañete F, Mañosa M, Casanova G-S, Barrio J, Bermejo F, Nos P, Iglesias-Flores E, García-Planella E, Pérez-Calle JL, Vicente R, Vera M, Ramos L, Rivero M, De Francisco R, Montserrat A, Benítez O, Navarro P, Taxonera C, Hinjoza E, Márquez-Mosquera L, Navarro-Llavat M, Ramírez-de la Piscina P, Gomollón F, Rodríguez-Alonso L, Núñez-Alonso A, Fernández-Salazar L, Almela P, Ríos León R, De Castro L, Gisbert JP, Ricart E, Cabré E, Domènech E (2019) Adalimumab or infliximab for the prevention of early postoperative recurrence of Crohn disease: results from the ENEIDA Registry. Inflamm Bowel Dis 25(11):1862–1870

32. Hanauer S, Korelitz B, Rutgeerts P, Peppercorn M, Thisted R, Cohen R, Present D (2004) Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 127(3):723–729

33. Kim NK, Senagore AJ, Luchtefeld MA, MacKeigan JM, Mazier WP, Belknap K, Chen SH (1997) Long-term outcome after ileocecal resection for Crohn’s disease. J Surg Res 63(7):627–633

34. Yamamoto T, Keighley MR (1999) The association of cigarette smoking with a high risk of recurrence after ileocolic resection for ileoceleal Crohn’s disease. Jpn J Surg 29(6):579–580

35. Rutgeerts P, Geboes K, Vantrappen G, Boley LS, Kerremans R, Hiele M (1990) Predictability of the postoperative course of Crohn’s disease. Gastroenterology 99(4):956–963

36. Riss S, Schuster I, Papay P, Herbst F, Mittlböck M, Chitsabesan P, Stift A (2014) Surgical recurrence after primary ileocolic resection for Crohn’s disease. Tech Coloproctol 18(4):365–371

37. Aaltonen G, Keränen I, Carpelan-Holmström M, Lepistö A (2018) Risk factors for anastomotic recurrence after primary ileoceleal resection in Crohn’s disease. Eur J Gastroenterol Hepatol 30(10):1143–1147

38. Rink AD, Fischer IR, Vestweber B, Vestweber KH (2014) Long-term outcome of laparoscopic ileocecal resection for Crohn’s disease before the era of biologics. Int J Colorectal Dis 29(1):127–132

39. Feagan BG, Panaccione R, Sandborn WJ, D’Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV Jr, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P (2008) Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the charm study. Gastroenterology 135(5):1493–1499

40. Orlando A, Mocciaro F, Renna S, Scimeca D, Rispo A, Scribano ML, Testa A, Aratari A, Bossa F, Tambasco R, Angelucci E, Onali S, Cappello M, Fries W, D’Incà R, Martinato M, Castiglione F, Papi C, Annese V, Gionchetti P, Rizzello F, Vernia P, Biancone L, Kohn A, Cottone M (2014) Early post-operative endoscopic recurrence in Crohn’s disease patients: data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort. J Crohns Colitis 8(10):1217–1221

41. Araki T, Uchida K, Okita Y, Fujikawa H, Inoue M, Ohi M, Tanaka K, Inoue Y, Mohri Y, Kusunoki M (2014) The impact of postoperative infliximab maintenance therapy on preventing the surgical recurrence of Crohn’s disease: a single-center paired case–control study. Surg Today 44(2):291–296

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.